G. Goldman

发表

Correction: Insights on the Impact of External and Internal Boosting on Varicella-Zoster Virus Reactivation Based on Evidence From the First Decade of the United States Universal Varicella Vaccination Program

G. Goldman, 2021, Cureus.

Insights on the Impact of External and Internal Boosting on Varicella-Zoster Virus Reactivation Based on Evidence From the First Decade of the United States Universal Varicella Vaccination Program

G. Goldman, 2021, Cureus.

Varicella disease after introduction of varicella vaccine in the United States, 1995-2000.

L. Mascola, M. Wharton, K. Brodovicz, 2002, JAMA.

CDC suppression of deleterious data associated with the US universal varicella vaccination program: the effect of declining exogenous exposures on herpes zoster incidence rates (Preprint)

G. Goldman, 2019 .

The Case against Universal Varicella Vaccination

G. Goldman, 2006, International journal of toxicology.

Universal Varicella Vaccination: Efficacy Trends and Effect on Herpes Zoster

G. Goldman, 2005, International journal of toxicology.

Cost-benefit analysis of universal varicella vaccination in the U.S. taking into account the closely related herpes-zoster epidemiology.

G. Goldman, 2005, Vaccine.

Response to Letter to the Editor by Jumaan: Goldman's role in the Varicella Active Surveillance Project.

G. Goldman, 2004, Vaccine.

Varicella susceptibility and incidence of herpes zoster among children and adolescents in a community under active surveillance.

G. Goldman, 2003, Vaccine.

Second varicella infections: are they more common than previously thought?

L. Mascola, M. Wharton, J. Seward, 2002, Pediatrics.

Examples of Outcome Reporting Bias in Vaccine Studies: Illustrating How Perpetuating Medical Consensus Can Impede Progress in Public Health

G. Goldman, 2022, Cureus.

A first checklist of macrofungi for South Africa

M. Gryzenhout, G. Ndiritu, G. Goldman, 2020, MycoKeys.

Review of the United States universal varicella vaccination program: Herpes zoster incidence rates, cost-effectiveness, and vaccine efficacy based primarily on the Antelope Valley Varicella Active Surveillance Project data

G. Goldman, P.G. King, 2013, Vaccine.

Using capture-recapture methods to assess varicella incidence in a community under active surveillance.

G. Goldman, 2003, Vaccine.

Infant mortality rates regressed against number of vaccine doses routinely given: Is there a biochemical or synergistic toxicity?

G. Goldman, Neil Z. Miller, 2011, Human & experimental toxicology.

Reaffirming a Positive Correlation Between Number of Vaccine Doses and Infant Mortality Rates: A Response to Critics

G. Goldman, Neil Z. Miller, 2023, Cureus.

Neonatal, Infant, and Under Age Five Vaccine Doses Routinely Given in Developed Nations and Their Association With Mortality Rates

G. Goldman, Neil Z. Miller, 2023, Cureus.

Incidence of herpes zoster among children and adolescents in a community with moderate varicella vaccination coverage.

G. Goldman, 2003, Vaccine.

Corrected: Insights on the Impact of External and Internal Boosting on Varicella-Zoster Virus Reactivation Based on Evidence From the First Decade of the United States Universal Varicella Vaccination Program

G. Goldman, 2021 .

biochemical or synergistic toxicity ? Infant mortality rates regressed against number of vaccine doses routinely given : Is there a

G. Goldman, Neil Z. Miller, 2011 .